Wave Life Sciences (WVE) | Financial Analysis & Statements
Wave Life Sciences Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
17.2M
Operating Income
-56.5M
-327.44%
Net Income
-53.2M
-308.37%
EPS (Diluted)
$-0.30
Balance Sheet Metrics
Total Assets
638.5M
Total Liabilities
120.1M
Shareholders Equity
518.4M
Debt to Equity
0.23
Cash Flow Metrics
Operating Cash Flow
-42.1M
Free Cash Flow
-33.8M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Wave Life Sciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 42.7M | 108.3M | 113.3M | 3.6M | 41.0M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 182.8M | 159.7M | 130.0M | 115.9M | 121.9M |
| Selling, General & Administrative | 75.3M | 59.0M | 51.3M | 50.5M | 46.1M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 258.1M | 218.7M | 181.3M | 166.4M | 168.0M |
| Operating Income | -215.4M | -110.4M | -68.0M | -162.7M | -127.0M |
| Operating Margin % | -504.1% | -101.9% | -60.0% | -4,459.3% | -310.1% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 11.0M | 13.4M | 9.8M | 1.6M | 4.6M |
| Pre-tax Income | -204.4M | -97.0M | -58.2M | -161.1M | -122.4M |
| Income Tax | 0 | 0 | -677.0K | 681.0K | -204.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -204.4M | -97.0M | -57.5M | -161.8M | -122.2M |
| Net Margin % | -478.3% | -89.6% | -50.8% | -4,434.7% | -298.4% |
| Key Metrics | |||||
| EBITDA | -217.0M | -111.9M | -66.7M | -154.2M | -117.2M |
| EPS (Basic) | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
| EPS (Diluted) | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
| Basic Shares Outstanding | 168649795 | 138277468 | 106097268 | 78855810 | 51825566 |
| Diluted Shares Outstanding | 168649795 | 138277468 | 106097268 | 78855810 | 51825566 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Wave Life Sciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 602.1M | 302.1M | 200.4M | 88.5M | 150.6M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.3M | 1.4M | 21.1M | 0 | 0 |
| Inventory | - | - | - | - | - |
| Other Current Assets | 3.1M | 7.4M | 4.0M | 2.1M | 5.4M |
| Total Current Assets | 614.8M | 320.4M | 235.4M | 98.5M | 162.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 12.5M | 17.9M | 22.6M | 26.8M | 18.4M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.8M | 3.8M | 3.9M | 3.7M | 3.8M |
| Total Non-Current Assets | 23.7M | 31.8M | 39.6M | 47.8M | 44.4M |
| Total Assets | 638.5M | 352.2M | 274.9M | 146.4M | 207.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 15.7M | 16.3M | 12.8M | 16.9M | 7.3M |
| Short-term Debt | 8.4M | 7.6M | 6.7M | 5.5M | 5.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 95.1M | 111.0M | 186.4M | 71.5M | 64.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 9.4M | 17.8M | 25.4M | 32.1M | 25.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | 190.0K | - |
| Total Non-Current Liabilities | 25.1M | 31.7M | 48.9M | 120.0M | 110.3M |
| Total Liabilities | 120.1M | 142.7M | 235.3M | 191.5M | 174.5M |
| Equity | |||||
| Common Stock | 1.6B | 1.2B | 935.4M | 802.8M | 749.9M |
| Retained Earnings | -1.3B | -1.1B | -1.0B | -967.3M | -805.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 518.4M | 209.5M | 39.6M | -45.1M | 32.5M |
| Key Metrics | |||||
| Total Debt | 17.8M | 25.4M | 32.1M | 37.6M | 29.9M |
| Working Capital | 519.7M | 209.4M | 48.9M | 27.0M | 98.4M |
Balance Sheet Composition
Wave Life Sciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -204.4M | -97.0M | -57.5M | -161.8M | -122.2M |
| Depreciation & Amortization | 8.9M | 8.7M | 9.2M | 10.1M | 9.8M |
| Stock-Based Compensation | 25.0M | 13.1M | 9.8M | 17.2M | 16.4M |
| Working Capital Changes | -23.6M | -80.4M | 21.8M | 5.4M | 270.0K |
| Operating Cash Flow | -194.1M | -155.6M | -16.7M | -129.1M | -95.7M |
| Investing Activities | |||||
| Capital Expenditures | -718.0K | -938.0K | -1.1M | -1.3M | -560.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | 0 | 0 | -75.0M | 0 |
| Investment Sales | - | 0 | 0 | 75.0M | 0 |
| Investing Cash Flow | -718.0K | -938.0K | -1.1M | -1.3M | -560.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 472.5M | 236.2M | 131.3M | 52.3M | 55.0M |
| Free Cash Flow | -188.2M | -152.0M | -20.5M | -129.1M | -89.6M |
| Net Change in Cash | 277.6M | 79.6M | 113.4M | -78.1M | -41.3M |
Cash Flow Trend
Wave Life Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-5.93
Forward P/E
-5.36
Price to Book
2.60
Price to Sales
31.64
PEG Ratio
0.02
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-327.44%
Return on Equity
-54.97%
Return on Assets
-27.18%
Financial Health
Current Ratio
6.47
Debt to Equity
3.38
Beta
-1.32
Per Share Data
EPS (TTM)
$-1.19
Book Value per Share
$2.76
Revenue per Share
$0.25
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| WVE | 1.4B | -5.93 | 2.60 | -54.97% | 0.00% | 3.38 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Amylyx | 1.9B | 2.54 | 6.31 | -61.59% | 0.00% | 1.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.






